Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Yusuf
dc.contributor.authorEren, Fatih
dc.contributor.authorColak, Yasar
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorCelikel, Cigdem Ataizi
dc.contributor.authorImeryuz, Nese
dc.date.accessioned2024-04-24T17:20:25Z
dc.date.available2024-04-24T17:20:25Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and aims. Syndecan-1 (CD 138) is a transmembrane heparan sulfate proteoglycan expressed in the liver which may exert metabolic effects by mediating the hepatic clearance of triglyceride-rich lipoproteins. In the present study, we assayed serum levels and the hepatic expression of syndecan-1 and examined their association with clinical, biochemical, and histologic phenotypes in patients with histology-proven nonalcoholic fatty liver disease (NAFLD). Methods. A total of 59 patients with biopsy-proven NAFLD and 54 matched controls were enrolled. The analysis of syndecan-1 expression in liver biopsies was performed by immunohistochemistry on formalin-fixed, paraffin-embedded samples. Serum syndecan-1 levels were measured by ELISA. Results. NAFLD patients had significantly higher serum syndecan-1 levels [median: 61 ng/mL (interquartile range: 36-97 ng/mL)] than controls [median: 37 ng/mL (interquartile range: 25-59 ng/mL, Mann Whitney U test, p < 0.001]. However, we did not find any significant association between serum syndecan-1 and the mean syndecan-1 immunohistochemical score (n = 59, r = 0.064, p = 0.63). Interestingly, the syndecan-1 immunohistochemical score was an independent predictor of HDL cholesterol in NAFLD patients (beta = 0.27; t = 1.99, p < 0.05). Conclusions. Our data suggest that serum syndecan-1 levels are raised in patients with NAFLD. Moreover, the syndecan-1 immunohistochemical score in the liver is independently associated with HDL cholesterol in this group of patients. These pilot results support further investigation of this molecule in metabolic liver diseases.en_US
dc.description.sponsorshipInstitute of Gastroenterology, Marmara University, Istanbul, Turkeyen_US
dc.description.sponsorshipThis study was financially supported by a grant from the Institute of Gastroenterology, Marmara University, Istanbul, Turkey. The authors report no conflicts of interest.en_US
dc.identifier.doi10.3109/00365521.2012.725093
dc.identifier.endpage1493en_US
dc.identifier.issn0036-5521
dc.identifier.issue12en_US
dc.identifier.pmid23137022
dc.identifier.scopus2-s2.0-84870036673
dc.identifier.scopusqualityQ3
dc.identifier.startpage1488en_US
dc.identifier.urihttps://doi.org/10.3109/00365521.2012.725093
dc.identifier.urihttps://hdl.handle.net/11468/19042
dc.identifier.volume47en_US
dc.identifier.wosWOS:000312427800012
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofScandinavian Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEnzyme-Linked Immunosorbent Assayen_US
dc.subjectImmunohistochemistryen_US
dc.subjectNonalcoholic Fatty Liver Diseaseen_US
dc.subjectSyndecan-1en_US
dc.titleHepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver diseaseen_US
dc.titleHepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu